# EQRx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eqrx

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.eqrx.com
- Total disclosed funding: $740M
- Latest round: Series B (Nov 2, 2020)
- Investors on record: 7

## About

Based in Massachusetts, US, and founded in 2019 by Alexis Borisy, Peter Bach, and Sandra Horning, EQRx, Inc. operates as a biotechnology company focused on manufacturing low-cost drugs for treating chronic diseases. In July 2023, Revolution Medicines, Inc. fully acquired EQRx, Inc. for USD 200 million in an all-stock deal. 

EQRx, Inc. manufactures drugs for the treatment of life-threatening and chronic diseases such as cancers, including lung, breast, and other solid tumors through the re-engineering process.

Following the merger, the firm plans to use the proceeds to continue building its clinical development organization, accelerate the business toward commercialization of its late-stage drug candidates, and continue to amass a robust pipeline of innovative medicines to address areas of burden.

## Funding rounds

- Series B, Nov 2, 2020, $500M — ARCH Venture Partners, Arboretum Ventures, Nextech, GV, Andreessen Horowitz, Casdin Capital, Section 32
- Series A, Jan 27, 2020, $240M — ARCH Venture Partners, Arboretum Ventures, Nextech, GV, Andreessen Horowitz, Casdin Capital, Section 32

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series A, Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series A, Series B
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A, Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series A, Series B